High-grade B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for High-grade B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma [NA]
This clinical trial update describes the use of nanochip technology to monitor treatment response and detect relapse in participants with di…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Long-term Study to Evaluate Safety and Persistence of GF-CART01
This clinical trial update describes a long-term safety and persistence study of GF-CART01, with enrollment not yet starting.
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating a triple combination of tafasitamab, retifanlimab, and rituximab with standard therapy for diffuse lar…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 clinical trial update for a glofitamab-based treatment in people with diffuse large B-cell lymphoma and high-grade B-cell lymphoma, …
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: Emapalumab Prevention of CAR-T Cell Associated Toxicities [Phase 2]
A Phase 2 clinical trial update evaluating emapalumab for preventing CAR-T cell–related toxicities in patients with relapsed or refractory B…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) [Phase 1]
Phase 1 clinical trial evaluating the combination of Rituximab and Tafasitamab with allogeneic NK cells in relapsed/refractory B-cell non-Ho…
-
CLINICAL_TRIALS research · 2025-10-20Clinical Trial Update: Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment [Phase 2]
This SWOG Cancer Research Network Phase 2 trial is evaluating adding drugs to standard therapy for large B-cell lymphoma that has returned o…
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma [Phase 1]
This Phase 1 trial evaluates low-dose radiation as bridging therapy for relapsed or refractory B-cell non-Hodgkin lymphomas, including DLBCL…
-
CLINICAL_TRIALS research · 2025-07-16Clinical Trial Update: A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) [Phase 1]
Phase 1 LOTIS-10 study assessing the pharmacokinetics and safety of loncastuximab tesirine in relapsed or refractory diffuse large B-cell ly…
-
CLINICAL_TRIALS research · 2025-06-08Clinical Trial Update: Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma [Phase 2]
This clinical trial update describes a Phase 2 study at the University of Chicago assessing pembrolizumab plus chemotherapy for untreated B-…
-
CLINICAL_TRIALS research · 2025-04-09Clinical Trial Update: Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure [Phase 2]
A Phase 2 clinical trial evaluating loncastuximab tesirine in patients with relapsed or refractory diffuse large B-cell lymphoma or high-gra…
-
CLINICAL_TRIALS research · 2025-03-27Clinical Trial Update: Epcoritamab-CAR T Cells for Large B-cell Lymphomas [Phase 2]
Phase 2 clinical trial evaluating epcoritamab-CAR T cells for large B-cell lymphomas, currently recruiting.
-
CLINICAL_TRIALS research · 2025-02-11Clinical Trial Update: Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL [Phase 2]
A Phase 2 clinical trial evaluating Relmacabtagene autoleucel as second-line therapy for adults with aggressive B-cell non-Hodgkin lymphomas…
-
CLINICAL_TRIALS research · 2025-01-28Clinical Trial Update: Immunotherapy in Lymphoma
An ongoing immunotherapy trial for relapsed or refractory B-cell lymphomas is currently recruiting. The study targets high-grade B-cell lymp…
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse [Phase 2]
Phase 2 trial evaluating Golcadomide after CAR T-cell therapy in adults with relapsed/refractory aggressive diffuse large B-cell lymphoma an…
-
CLINICAL_TRIALS research · 2024-07-22Clinical Trial Update: Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL [Phase 2]
Phase 2 clinical trial evaluating salvage therapy that includes epcoritamab (Epcor) followed by autologous stem cell transplant and epcorita…
-
CLINICAL_TRIALS research · 2017-02-24Clinical Trial Update: Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults
This clinical trial update presents a retrospective analysis of rituximab-containing immunochemotherapy for adults with Burkitt lymphoma or …